[go: up one dir, main page]

WO2004030629A3 - Novel neurokinin antagonists and methods of use thereof - Google Patents

Novel neurokinin antagonists and methods of use thereof Download PDF

Info

Publication number
WO2004030629A3
WO2004030629A3 PCT/US2003/031153 US0331153W WO2004030629A3 WO 2004030629 A3 WO2004030629 A3 WO 2004030629A3 US 0331153 W US0331153 W US 0331153W WO 2004030629 A3 WO2004030629 A3 WO 2004030629A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurokinin
tachykinin
disorders
methods
nervous system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2003/031153
Other languages
French (fr)
Other versions
WO2004030629A2 (en
Inventor
Oren Becker
Dale S Dhanoa
Silvia Noiman
Anurag Sharadendu
Venkitasamy Kesavan
Pradyumna Mohanty
Yael Marantz
Ori Kalid
Dongli Chen
Sacham Sharon
Raphael Nudelman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PREDIX PHARMACEUTICALS
Original Assignee
PREDIX PHARMACEUTICALS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PREDIX PHARMACEUTICALS filed Critical PREDIX PHARMACEUTICALS
Priority to AU2003277215A priority Critical patent/AU2003277215A1/en
Publication of WO2004030629A2 publication Critical patent/WO2004030629A2/en
Publication of WO2004030629A3 publication Critical patent/WO2004030629A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/04—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to tachykinin receptor antagonists, the tachykinin family of receptors comprising the neurokinins substance P (SP), neurokinin A, and neurokinin B and related neuropeptides that are widely distributed in the peripheral and central nervous system. The present invention discloses novel neurokinin antagonists represented by formulas I-IV, and synthesis and uses thereof for treating diseases mediated directly or indirectly by the tachykinin receptors. Such conditions include central nervous system disorders such as anxiety, pain, depression, emesis, e.g., cancer chemotherapy-induced emesis, respiratory and inflammatory to bowel disease and other gastric disorders, asthma, schizophrenia, ophthalmic diseases such as glaucoma, ocular hypotension, neural injury, stroke, cardiac disorders, psoriasis, and migraine. Methods of preparation and novel intermediates and pharmaceutical salts thereof are also included.
PCT/US2003/031153 2002-10-01 2003-09-30 Novel neurokinin antagonists and methods of use thereof Ceased WO2004030629A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003277215A AU2003277215A1 (en) 2002-10-01 2003-09-30 Novel neurokinin antagonists and methods of use thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US41504502P 2002-10-01 2002-10-01
US60/415,045 2002-10-01
US42518702P 2002-11-08 2002-11-08
US42513002P 2002-11-08 2002-11-08
US42518602P 2002-11-08 2002-11-08
US60/425,130 2002-11-08
US60/425,186 2002-11-08
US60/425,187 2002-11-08

Publications (2)

Publication Number Publication Date
WO2004030629A2 WO2004030629A2 (en) 2004-04-15
WO2004030629A3 true WO2004030629A3 (en) 2004-11-04

Family

ID=32074647

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/031153 Ceased WO2004030629A2 (en) 2002-10-01 2003-09-30 Novel neurokinin antagonists and methods of use thereof

Country Status (2)

Country Link
AU (1) AU2003277215A1 (en)
WO (1) WO2004030629A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7488736B2 (en) 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7407966B2 (en) 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7576211B2 (en) 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
DE102004055998A1 (en) * 2004-11-19 2006-05-24 Rheinische Friedrich-Wilhelms-Universität Bonn Low molecular weight inhibitors of guanine nucleotide exchange factors of the cytohesin family
CA2727055C (en) 2008-01-11 2016-12-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
US8114894B2 (en) 2008-12-03 2012-02-14 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
WO2011003021A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
WO2011003012A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azinone-substituted azapolycycle mch-1 antagonists, methods of making, and use thereof
EP2448585B1 (en) 2009-07-01 2014-01-01 Albany Molecular Research, Inc. Azinone-substituted azepino[b]indole and pyrido-pyrrolo-azepine mch-1 antagonists, methods of making, and use thereof
WO2011003007A1 (en) 2009-07-01 2011-01-06 Albany Molecular Research, Inc. Azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
US8993765B2 (en) 2010-12-21 2015-03-31 Albany Molecular Research, Inc. Tetrahydro-azacarboline MCH-1 antagonists, methods of making, and uses thereof
US8697700B2 (en) 2010-12-21 2014-04-15 Albany Molecular Research, Inc. Piperazinone-substituted tetrahydro-carboline MCH-1 antagonists, methods of making, and uses thereof
WO2018130123A1 (en) * 2017-01-11 2018-07-19 南京圣和药业股份有限公司 Pentacyclic compound as selective estrogen receptor down-regulator and use thereof
CN112955433A (en) 2017-09-08 2021-06-11 赛伯克斯股份有限公司 Compounds, compositions and methods for selectively inhibiting beta-glucuronidase and reducing side effects associated with drug therapy-induced diarrhea

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981029, Database accession no. 2003:1788360 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981030, Database accession no. 2003:1788092 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981031, Database accession no. 2002:2019309 *
DATABASE CHEMCATS [online] 9 July 2002 (2002-07-09), XP002981032, Database accession no. 2003:1788391 *

Also Published As

Publication number Publication date
AU2003277215A8 (en) 2004-04-23
AU2003277215A1 (en) 2004-04-23
WO2004030629A2 (en) 2004-04-15

Similar Documents

Publication Publication Date Title
WO2004014850A3 (en) Substituted aminopyrimidines as neurokinin antagonists
WO2004030629A3 (en) Novel neurokinin antagonists and methods of use thereof
WO2004069794A3 (en) New arylpiperazinyl compounds
WO2004089312A3 (en) New piperidinylamino-thieno[2,3-d] pyrimidine compounds
JP5705249B2 (en) Substituted pyridine derivatives
DE69633607T2 (en) Piperidin derivatives with tachykinin-antagonist activity
DE69628035T2 (en) PIPERIDINE ANALOGS SUBSTITUTED IN 4-POSITION AND THEIR USE AS SUBTYPE-SELECTIVE NMDA RECEPTOR ANTAGONISTS
DE69425662T2 (en) PIPERAZINE CONNECTIONS USED AS A MEDICINE
DE60027011T2 (en) Urea derivatives as CCR-3 receptor inhibitors
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
CN103889968A (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
UA88719C2 (en) Histamine-3 receptor antagonists
MA27847A1 (en) AZETIDINE DERIVATIVES SUBSTITUTED WITH 3-ALKYL AND 3-ALKENYL.
CN103180299A (en) Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
EP2468732B1 (en) 1H-Quinazoline-2,4-diones
TW201605840A (en) Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104011028A (en) N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
HUE031661T2 (en) Combinations of serotonin receptor agonists for treatment of movement disorders
CN104955826B (en) It can be used for treating spiral shell-Quinzolone derivatives of neurological disorder and illness
EA200500173A1 (en) 3,6-DISPOSABLE AZABICYCLO [3.1.0] HEXANE DERIVATIVES AS ANTAGONISTS OF MUSCARIN RECEPTORS
Manera et al. Rational design, synthesis, and pharmacological properties of new 1, 8-naphthyridin-2 (1 H)-on-3-carboxamide derivatives as highly selective cannabinoid-2 receptor agonists
EP0740658B1 (en) N-substituted azabicycloheptane derivatives used, for example, as neuroleptics
BR0309778A (en) 3,4-Dihydroquinolin-2 (1h) -one compounds as nr2b receptor antagonists
EA200701345A1 (en) Derivatives of triazolone, tetrazolone and imidazolone for use as antagonists of alpha-2c-adrenoreceptor

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP